IL2 and acute myeloid leukemia: In a human trial, patients with relapsed or refractory AML who were not candidates for HSCT underwent fludarabine/cyclophosphamide conditioning and infusion of haplo memory-like NK cells (obtained from apheresis product which underwent CD3+ depletion, CD56+ selection, and preactivation with IL-12, IL-15, and IL-18 for 12–16 hours), followed by in vivo IL-2.